Filing Flows › Evolent Health (EVH) › Takeover & LBO
Is Evolent Health (EVH) a takeover target?
A leveraged buyout does not work for Evolent Health on its latest figures: it has no positive EBITDA to borrow against (−$325M over the last 12 months, on revenue of $2.3B). Historically 6.0% of companies with its figures were bought within a year (1.19× the average).
Why a leveraged buyout does not fit
A leveraged buyout is paid for mostly with debt that the company's own cash flow repays. Evolent Health's EBITDA over the last 12 months was −$325M on revenue of $2.3B, so there is nothing to lend against and nothing to repay a loan with: a buyer would have to pay almost entirely with its own money. That is the kind of deal another company — a strategic buyer that wants the products, the pipeline or the technology — makes, not a private-equity fund. The model therefore gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 40% over the share price before the deal (the middle half 14.7% to 60.2%), according to the 20 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Evolent Health would cost about $6.02 a share, $681M for all its shares.
| Premium | % | Price a share | All shares |
|---|---|---|---|
| Low end (a quarter of deals paid less) | 14.7% | $4.93 | $558M |
| Median | 40% | $6.02 | $681M |
| High end (a quarter paid more) | 60.2% | $6.89 | $779M |
The odds, from history
Historically 6.0% of companies with its figures were bought within a year (1.19× the average). Its figures put it in decile 8 of 10 (10 = the most likely to be bought). The odds come from a model of every merger proxy, tender-offer response and going-private statement filed on EDGAR since 2011, set against each company's size, margins, debt, cash flow and growth the year before.
Evolent Health's latest quarter
Evolent Health, Q3 2026: revenue $725M (+51% year over year), operating margin -0.9%, net loss $23.6M, operating cash flow $26.4M. The chart follows the revenue to costs, profit and cash.
Questions
Is Evolent Health being acquired?
No headline, 8-K or 13D about a sale is on file in the last year.
Could private equity buy Evolent Health?
A leveraged buyout does not work for Evolent Health on its latest figures: it has no positive EBITDA to borrow against (−$325M over the last 12 months, on revenue of $2.3B). With no cash flow to repay a loan, a buyer would pay almost entirely with its own money: a deal for another company (a strategic buyer), not for a private-equity fund.
What would a takeover of Evolent Health cost?
Takeovers in its sector paid a median premium of 40% over the share price before the deal (the middle half 14.7% to 60.2%), according to the 20 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Evolent Health would cost about $6.02 a share, $681M for all its shares.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.